Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Kazia Therapeutics Ltd. (AU)

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in other forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020. In March 2021, Kazia licensed Greater China rights for paxalisib to Simcere Pharmaceutical Company. *

 

Period Start 2020-04-12 existent
Products Industry cancer drug
  Industry 2 drug development
Persons Person Garner, James (Kazia Therapeutics 202004 CEO joined 2016 before Sanofi in Singapore + Bain & Co)
  Person 2 Ross, Iain (201704 Board Member at several UK firms before Silence Therapeutics + Allergy Therapeutics + Quadrant)
     
Region Region Sydney NSW
  Country Australia
  Street 300 Barangaroo Avenue
Three International Towers, Level 24
  City 2000 Sydney NSW
    Address record changed: 2021-01-20
     
Basic data Employees n. a.
     
    * Document for �About Section�: Evotec SE. (4/19/21). "Press Release: Evotec Enters Partnership with Kazia Therapeutics for Clinical Development of EVT801". Hamburg.
     
   
Record changed: 2021-04-21

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Kazia Therapeutics Ltd. (AU)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top